Cognition Therapeutics CEO to Present at Key Investor Conferences
Event summary
- Cognition Therapeutics CEO Lisa Ricciardi to present at Jefferies Global Healthcare Conference on June 4, 2026.
- Ricciardi will also present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, available on-demand from June 15, 2026.
- Presentations will focus on plans for a registration program in DLB psychosis for lead candidate zervimesine (CT1812).
- Zervimesine has shown promise in Phase 2 trials for DLB and Alzheimer’s disease.
- Company has received nearly $200 million in NIH and related foundation grants.
The big picture
Cognition Therapeutics is positioning itself as a key player in the neurodegenerative disease space, with a focus on DLB psychosis. The upcoming investor presentations come at a critical juncture as the company prepares to advance its lead candidate, zervimesine, into late-stage clinical trials. The biopharmaceutical sector is increasingly focused on innovative therapies for neurodegenerative disorders, and Cognition's progress could attract significant investor attention.
What we're watching
- Clinical Development
- How the Phase 2 SHIMMER study results will translate into late-stage trials for DLB psychosis.
- Market Strategy
- Whether Cognition can capitalize on the unmet need in DLB psychosis to accelerate regulatory approval.
- Funding Dynamics
- The pace at which the company can secure additional grant funding to support its clinical programs.
Related topics